Understand the source comparison
Best DSIP Dosage for Pain Management: Research Comparison
1–2 mg 3×/week Mild inflammatory pain 20–30% vs baseline Minimal 2–4 weeks Subtherapeutic for moderate-to-severe pain. Reserve for low-intensity models or combination protocols with NSAIDs 5 mg 3×/week Moderate inflammatory, neuropathic 50–65% vs baseline Low
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- 1–2 mg 3×/week
- Mild inflammatory pain
- 20–30% vs baseline
- Minimal
- 2–4 weeks
- Subtherapeutic for moderate-to-severe pain. Reserve for low-intensity models or combination protocols with NSAIDs
- 5 mg 3×/week
- Moderate inflammatory, neuropathic
- 50–65% vs baseline
- Low (monitored at 8+ weeks)
- 4–8 weeks
- Gold standard protocol. Consistent across multiple pain model categories, receptor adaptation rare before week 10
- 7–8 mg 3×/week
- Severe neuropathic, cancer pain models
- 55–70% vs baseline
- Moderate (detectable at 6 weeks)
- Maximum 6 weeks
- Marginal benefit over 5 mg with faster tolerance. Consider only if 5 mg shows inadequate response after 3 weeks
- 10 mg 3×/week
- Refractory chronic pain
- 40–55% vs baseline
- High (significant by week 4)
- Not recommended beyond 4 weeks
- Paradoxically less effective than 5 mg due to receptor saturation. Appropriate only for acute pain surge management
- 10 mg pre-op + 5 mg post-op
- Acute surgical pain
- 60–75% vs saline control
- Minimal (short duration)
- 7–10 days post-surgery
- Front-loading strategy for perioperative analgesia. Effective but requires precise timing relative to tissue trauma